Optimize Financial Inc Invests $497,000 in Krystal Biotech, Inc. $KRYS

Optimize Financial Inc purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,815 shares of the company’s stock, valued at approximately $497,000.

Several other institutional investors also recently bought and sold shares of the company. State Street Corp lifted its stake in shares of Krystal Biotech by 10.5% in the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after acquiring an additional 128,639 shares during the period. Soleus Capital Management L.P. raised its holdings in Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares in the last quarter. Braidwell LP lifted its position in Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after purchasing an additional 327,067 shares during the period. Geode Capital Management LLC lifted its position in Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after purchasing an additional 7,194 shares during the period. Finally, Hood River Capital Management LLC boosted its holdings in Krystal Biotech by 1.6% in the 2nd quarter. Hood River Capital Management LLC now owns 533,023 shares of the company’s stock valued at $73,269,000 after purchasing an additional 8,379 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on KRYS shares. Chardan Capital increased their target price on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. The Goldman Sachs Group boosted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $277.89.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Trading Down 3.7%

NASDAQ:KRYS opened at $269.13 on Thursday. The company has a market capitalization of $7.80 billion, a P/E ratio of 40.35 and a beta of 0.49. The firm has a 50-day moving average price of $254.80 and a two-hundred day moving average price of $199.79. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $295.98.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.